Wells Fargo analyst Larry Biegelsen downgraded Novocure (NVCR) to Equal Weight from Overweight with a price target of $14.50, down from $40.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR: